Clinical trial · no report yet · Phase 2
NCT03554083
Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma
- NCT03554083 ↗
- Completed
- Mayo Clinic
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| YouTube | 1 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Neoadjuvant Therapy for Patients With High Risk Stage III Melanoma: A Pilot Clinical Trial
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage III Cutaneous Melanoma AJCC v8; Pathologic Stage IIIA Cutaneous Melanoma AJCC v8; Pathologic Stage IIIB Cutaneous Melanoma AJCC v8; Pathologic Stage IIIC Cutaneous Melanoma AJCC v8; Pathologic Stage IIID Cutaneous Melanoma AJCC v8
- Interventions
- Atezolizumab; Cobimetinib; Tiragolumab; Vemurafenib
- Arms
- Arm A - CLOSED (vemurafenib, cobimetinib, atezolizumab) · Experimental
- Arm B - CLOSED (cobimetinib, atezolizumab) · Experimental
- Arm C (atezolizumab, tiragolumab) · Experimental
- Enrollment
- 64
- Primary outcomes
- Pathologic Complete Response Rate (pCR)
- Median Recurrence-free (RFS) Rate (Adjuvant Phase)
- Sponsor
- Mayo Clinic
- Start
- Oct 5, 2018
- Primary completion
- Apr 30, 2025
- Results posted
- Yes
- Registry record
- NCT03554083 · updated May 4, 2026
Publications
linked from the registry- Hieken TJ, Nelson GD, Flotte TJ, Grewal EP, Chen J, McWilliams RR, Kottschade LA, Yang L, Domingo-Musibay E, Dronca RS, Yan Y, Markovic SN, Dimou A, Montane HN, Erskine CL, Piltin MA, Price DL, Khariwala SS, Hui J, Strand CA, Harrington SM, Suman VJ, Dong H, Block MS. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable Stage III melanoma: the Phase II NeoACTIVATE trial. Nat Commun. 2024 Feb 16;15(1):1430. doi: 10.1038/s41467-024-45798-8. PubMed 38365756
- Block MS, Nelson GD, Chen J, Johnson S, Yang L, Flotte TJ, Grewal EP, McWilliams RR, Kottschade LA, Domingo-Musibay E, Markovic SN, Dimou A, Montane HN, Piltin MA, Price DL, Khariwala SS, Hui JYC, Erskine CL, Strand CA, Zahrieh D, Dong H, Hieken TJ. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial. J Immunother Cancer. 2025 Apr 15;13(4):e011706. doi: 10.1136/jitc-2025-011706. PubMed 40234093
- Hieken TJ, Price DL, Piltin MA, Turner HJ, Block MS. Surgeon Assessment of the Technical Impact of Neoadjuvant Systemic Therapy on Operable Stage III Melanoma. Ann Surg Oncol. 2022 Feb;29(2):780-786. doi: 10.1245/s10434-021-11112-9. Epub 2021 Nov 25. PubMed 34825282